{"id":"W2126372889","doi":"10.1158/1078-0432.ccr-06-2610","title":"Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Rash; Erlotinib; Internal medicine; Medicine; Gefitinib; Gemcitabine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Hazard ratio; Gastroenterology; Oncology; Cancer; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1488288453879716,"score_gpt":0.5328739408514896,"score_spread":0.3840450954635181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}